Showing results (31-40 of 290) with videos related to
Sort By:
Pageof 29
Plos Medicine|March 2, 2005
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainWilliam Pao, Vincent A Miller, Katerina A Politi, et al.JCO Precision Oncology|September 14, 2020
Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma SpecimensMargaret A Hay, Eric A Severson, Vincent A Miller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic indexYuhong She, Fei Lee, Jing Chen, et al.Lung Cancer (Auckland, N.Z.)|May 31, 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burdenAnkur R Parikh, Siraj M Ali, Alexa B Schrock, et al.Lung Cancer (Amsterdam, Netherlands)|April 9, 2015
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profilingSai-Hong Ignatius Ou, Zachary R Chalmers, Michele C Azada, et al.Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinibSandeep Kodityal, Julia A Elvin, Rachel Squillace, et al.Chest|September 18, 2007
Pulmonary toxicity associated with erlotinibVincent Liu, Dorothy A White, Maureen F Zakowski, et al.Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.The Oncologist|May 17, 2017
Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNAAndrea Z Lai, Alexa B Schrock, Rachel L Erlich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutationsPaul K Paik, Maria E Arcila, Michael Fara, et al.Pageof 29